Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors
PET/CT using 68Ga-labeled somatostatin analogs (SSA) targeting somatostatin receptors (SSR) on the cell surface of well-differentiated neuroendocrine tumors (NET) represents the clinical reference standard for imaging. However, economic and logistic challenges of the 68Ge/68Ga generator-based approa...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2020
|
| In: |
European journal of nuclear medicine and molecular imaging
Year: 2019, Volume: 47, Issue: 4, Pages: 870-880 |
| ISSN: | 1619-7089 |
| DOI: | 10.1007/s00259-019-04501-6 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00259-019-04501-6 |
| Author Notes: | Harun Ilhan, S. Lindner, A. Todica, C.C. Cyran, R. Tiling, C.J. Auernhammer, C. Spitzweg, S. Boeck, M. Unterrainer, F.J. Gildehaus, G. Böning, K. Jurkschat, C. Wängler, B. Wängler, R. Schirrmacher, P. Bartenstein |
| Summary: | PET/CT using 68Ga-labeled somatostatin analogs (SSA) targeting somatostatin receptors (SSR) on the cell surface of well-differentiated neuroendocrine tumors (NET) represents the clinical reference standard for imaging. However, economic and logistic challenges of the 68Ge/68Ga generator-based approach have disadvantages over 18F-labeled compounds. Here, we present the first in-human data of 18F-SiFAlin-TATE, a novel 18F-labeled, SSR-targeting peptide. The aim was to compare the intra-individual biodistribution, tumor uptake, and image quality of 18F-SiFAlin-TATE to the clinical reference standard 68Ga-DOTA-TOC. |
|---|---|
| Item Description: | Gesehen am 23.06.2020 Published online: 6 September 2019 |
| Physical Description: | Online Resource |
| ISSN: | 1619-7089 |
| DOI: | 10.1007/s00259-019-04501-6 |